Peter Paul Toth, MD, PhD
January 15th, 2013
Is HDL Fool’s Gold?
Peter Paul Toth, MD, PhD
Peter P. Toth offers his perspective on recent trials of niacin, including HPS2-THRIVE and AIM-HIGH.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?